Literature DB >> 16291272

Successful treatment of MRSA native valve endocarditis with oral linezolid therapy: a case report.

N Nathani1, P Iles, T S J Elliott.   

Abstract

Staphylococcal endocarditis is potentially fatal and is now the most common cause of infective endocarditis with a mortality rate of 25-47% [Hecht SR, Berger M. Right-sided endocarditis in intravenous drug users: prognostic features in 102 episodes. Ann Intern Med 1992;117:560-6]. Its treatment requires maintenance of bactericidal level of antibiotics for prolonged periods to attain a culture-negative state. Although intravenous vancomycin is currently the drug of choice for methicillin resistant Staphylococcus aureus (MRSA) endocarditis, we present a case treated successfully with oral linezolid for 4 weeks due to a lack of venous access.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16291272     DOI: 10.1016/j.jinf.2005.02.016

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  3 in total

Review 1.  Infective endocarditis treated with linezolid: case report and literature review.

Authors:  E E Hill; P Herijgers; M-C Herregods; W E Peetermans
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-03       Impact factor: 3.267

2.  Successful medical treatment of bioprosthetic pulmonary valve endocarditis caused by methicillin-resistant Staphylococcus aureus.

Authors:  Claire A Irving; Donna Kelly; F Kate Gould; John J O'Sullivan
Journal:  Pediatr Cardiol       Date:  2010-01-10       Impact factor: 1.655

3.  An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy.

Authors:  Richard R Watkins; Tracy L Lemonovich; Thomas M File
Journal:  Core Evid       Date:  2012-12-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.